Evidence map›Paper›PMID 36143181›Full record

ArticleJournal of personalized medicine2022

Elevated Expression of

Eden Avnat, Guy Shapira, David Gurwitz, Noam Shomron

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eden AvnatFaculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.ORCID 0000-0002-5455-0994
Guy ShapiraFaculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.ORCID 0000-0001-9376-4955
David GurwitzFaculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.ORCID 0000-0002-9363-1869
Noam ShomronFaculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.ORCID 0000-0001-9913-6124
Tel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anosmia is common in COVID-19 patients, lasting for weeks or months following recovery. The biological mechanism underlying olfactory deficiency in COVID-19 does not involve direct damage to nasal olfactory neurons, which do not express the proteins required for SARS-CoV-2 infection. A recent study suggested that anosmia results from downregulation of olfactory receptors. We hypothesized that anosmia in COVID-19 may also reflect SARS-CoV-2 infection-driven elevated expression of regulator of G protein signaling 2 (

Indexed as

anosmiaCOVID-19CXCL8NAMPTnasopharyngeal epithelial cellsPTGS2RGS2RNA-sequencingSARS-CoV-2

Identifiers

PMID36143181
PMCPMC9504192
OpenAlexW4293759917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.